表紙
市場調查報告書

開發中的諾羅病毒疫苗:市場預測 (2020-2030年)

Global Norovirus Vaccines in Pipeline Forecast 2020-2030: Takeda, Vaxart, Cocrystal Pharma, PanTheryx, Calici Therapeutics

出版商 Visiongain Ltd 商品編碼 927174
出版日期 內容資訊 英文 98 Pages
商品交期: 最快1-2個工作天內
價格
開發中的諾羅病毒疫苗:市場預測 (2020-2030年) Global Norovirus Vaccines in Pipeline Forecast 2020-2030: Takeda, Vaxart, Cocrystal Pharma, PanTheryx, Calici Therapeutics
出版日期: 2019年12月19日內容資訊: 英文 98 Pages
簡介

全球開發中的諾羅病毒疫苗的市場在預測期間內預計將以7.6%%的年複合成長率 (CAGR) 成長。預計2022年的各地區佔有率北美地區佔61%。

本報告提供全球開發中的諾羅病毒疫苗的市場調查,諾羅病毒概要、流行病學,市場成長的各種影響因素分析,諾羅病毒疫苗候補,開發的課題,臨床試驗環境,各地區、主要國家的市場成長預測,主要企業簡介等資訊彙整。

第1章 報告概要

第2章 開發中的諾羅病毒疫苗:市場概要

  • 簡介
  • 市場動態
  • 全球諾羅病毒負擔
  • 諾羅病毒的流行病學

第3章 諾羅病毒疫苗

  • 疫苗候補
    • 基因轉殖植物為基礎
    • P粒子、並用疫苗
    • 3價諾羅病毒/輪狀病毒並用疫苗
    • 武田藥品工業、Ligocyte VLP疫苗
  • 諾羅病毒疫苗開發的課題
  • 諾羅病毒疫苗:臨床試驗環境

第4章 市場預測:各地區、主要國家

  • 北美
  • 歐盟5國
  • 亞太地區
  • 中南美
  • 中東、非洲

第5章 主要企業

  • 武田藥品工業
  • Vaxart
  • Cocrystal Pharma, Inc.
  • PanTheryx
  • Calici Therapeutics

附錄

目錄
Product Code: PHA0643

The global norovirus vaccines market is estimated to grow at a CAGR of 7.6% during the forecast period. In 2022, North America is expected to hold a market share of 61% of the global norovirus vaccines market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

The report provides clear detailed insight into the global norovirus vaccines in pipeline forecast. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Global Norovirus Vaccines in Pipeline forecast from 2020-2030

Global Norovirus Vaccines in Pipeline forecast from 2020-2030 by Regional and National Market:

  • North America: US, Canada
  • EU5: Germany, France, UK, Italy, Spain
  • APAC: Japan, China, India, Australia, ASEAN, Rest of APAC
  • Central and South America: Brazil, Argentina, Rest of Central and South America
  • Middle East and Africa: GCC, South Africa, North Africa, Rest of MEA

Profiles of the selected leading companies:

  • Calici Therapeutics
  • Cocrystal Pharma
  • PanTheryx
  • Takeda
  • Vaxart
  • List and discussion of candidate vaccines

Key Questions Answered by this Report:

  • What is the current size of the overall global norovirus vaccines market? How much will this market be worth from 2020 to 2030?
  • What are the main drivers and restraints that will shape the overall norovirus vaccine market over the next ten years?
  • What factors will affect that industry and market over the next ten years?
  • What are the largest national markets for the world vaccines? What is their current status and how will they develop over the next ten years? What are their revenue potentials to 2030?
  • How will market shares of the leading national markets change by 2030, and which geographical region will lead the market in 2030?
  • Who are the leading companies and what are their activities, results, developments and prospects?
  • What are some of the most prominent norovirus vaccines currently in development?
  • What are the main trends that will affect the world norovirus vaccines market between 2020 and 2030?
  • What are the main strengths, weaknesses, opportunities and threats for the market?
  • What are the demographic influences that will shape that industry over the next ten years?
  • How will the global norovirus vaccines market evolve over the forecasted period, 2020 to 2030?

Buy our report today Global Norovirus Vaccines in Pipeline Forecast 2020-2030: Takeda, Vaxart, Cocrystal Pharma, PanTheryx, Calici Therapeutics.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1 Overview of the World Norovirus Vaccines Market
  • 1.2 Why You Should Read this Report
  • 1.3 How This Report Delivers
  • 1.4 Main Questions Answered by this Analytical Study
  • 1.5 Who is This Report for?
  • 1.6 Methods of Research and Analysis
  • 1.7 Frequently Asked Questions (FAQ)
  • 1.8 Associated Visiongain Reports
  • 1.9 About Visiongain

2 Norovirus Vaccines in Pipeline Market Overview

  • 2.1 Introduction
  • 2.2 Market Dynamics
    • 2.2.1 Growing Demand from Under-Developed and Developing Economies
    • 2.2.2 Ensuring that Vaccines Benefit Global Public Health
    • 2.2.3 Increased Investment Requirements for R&D and Manufacturing
    • 2.2.4 Increased opportunity cost as relative investment economics converge with biologics
    • 2.2.5 Sensitive assays have only recently been widely available
    • 2.2.6 Routine testing is rarely performed in ongoing surveillance platforms
  • 2.3 Global Burden of Norovirus
    • 2.3.1 Role of Norovirus
    • 2.3.2 Global trends of diarrheal disease in adults and children
  • 2.4 Epidemiology of norovirus
    • 2.4.1 Risk factors, modes and settings of transmission
    • 2.4.2 Early childhood infections
    • 2.4.3 Chronic health consequences associated with norovirus infection

3 Norovirus vaccines

  • 3.1 Candidate vaccines
    • 3.1.1 Transgenic plant-based norovirus vaccine
    • 3.1.2 Norovirus P particle and combination vaccines
    • 3.1.3 Trivalent norovirus /rotavirus combination vaccine
    • 3.1.4 Takeda Pharmaceutical/Ligocyte VLP vaccine
  • 3.2 Challenges for norovirus vaccine development
  • 3.3 Norovirus Vaccines: Clinical Trial Landscape

4 Global Norovirus Vaccine Market Forecast, 2020-2030 (USD Million)

  • 4.1 North America Norovirus Vaccine Market Forecast, 2020-2030 (USD Million)
    • 4.1.1 U.S. Norovirus Vaccine Market Forecast, 2020-2030 (USD Million)
    • 4.1.2 Canada Norovirus Vaccine Market Forecast, 2020-2030 (USD Million)
  • 4.2 EU5 Norovirus Vaccine Market Forecast, 2020-2030 (USD Million)
    • 4.2.1 Germany Norovirus Vaccine Market Forecast, 2020-2030 (USD Million)
    • 4.2.2 The UK Norovirus Vaccine Market Forecast, 2020-2030 (USD Million)
    • 4.2.3 France Norovirus Vaccine Market Forecast, 2020-2030 (USD Million)
    • 4.2.4 Italy Norovirus Vaccine Market Forecast, 2020-2030 (USD Million)
    • 4.2.5 Spain Norovirus Vaccine Market Forecast, 2020-2030 (USD Million)
  • 4.3 APAC Norovirus Vaccine Market Forecast, 2020-2030 (USD Million)
    • 4.3.1 Japan Norovirus Vaccine Market Forecast, 2020-2030 (USD Million)
    • 4.3.2 China Norovirus Vaccine Market Forecast, 2020-2030 (USD Million)
    • 4.3.3 India Norovirus Vaccine Market Forecast, 2020-2030 (USD Million)
    • 4.3.4 Australia Norovirus Vaccine Market Forecast, 2020-2030 (USD Million)
    • 4.3.5 ASEAN Norovirus Vaccine Market Forecast, 2020-2030 (USD Million)
    • 4.3.6 Rest of APAC Norovirus Vaccine Market Forecast, 2020-2030 (USD Million)
  • 4.4 Central and South America Norovirus Vaccine Market Forecast, 2020-2030 (USD Million)
    • 4.4.1 Brazil Norovirus Vaccine Market Forecast, 2020-2030 (USD Million)
    • 4.4.2 Argentina Norovirus Vaccine Market Forecast, 2020-2030 (USD Million)
    • 4.4.3 Rest of Central and South America Norovirus Vaccine Market Forecast, 2020-2030 (USD Million)
  • 4.5 MEA Norovirus Vaccine Market Forecast, 2020-2030 (USD Million)
    • 4.5.1 GCC Norovirus Vaccine Market Forecast, 2020-2030 (USD Million)
    • 4.5.2 South Africa Norovirus Vaccine Market Forecast, 2020-2030 (USD Million)
    • 4.5.3 North Africa Norovirus Vaccine Market Forecast, 2020-2030 (USD Million)
    • 4.5.4 Rest of MEA Norovirus Vaccine Market Forecast, 2020-2030 (USD Million)

5 Leading Companies

  • 5.1 Takeda Pharmaceutical Company Limited
    • 5.1.1 Company Overview
    • 5.1.2 Financial Performance (2016-2018)
    • 5.1.3 Pipeline Products
  • 5.2 Vaxart
    • 5.2.1 Company Overview
    • 5.2.2 Financial Performance
    • 5.2.3 Pipeline Products
  • 5.3 Cocrystal Pharma, Inc.
    • 5.3.1 Company Overview
    • 5.3.2 Pipeline Products
  • 5.4 PanTheryx
    • 5.4.1 Company Overview
    • 5.4.2 Pipeline Products
  • 5.5 Calici Therapeutics
    • 5.5.1 Company Overview
    • 5.5.2 Pipeline Products

Appendices

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form

List of Tables

  • Table 4.1 Global Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2020-2030
  • Table 4.2 North America Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2020-2030
  • Table 4.3 U.S. Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2020-2030
  • Table 4.4 Canada Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2020-2030
  • Table 4.5 EU5 Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2020-2030
  • Table 4.6 Germany Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2020-2030
  • Table 4.7 The UK Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2020-2030
  • Table 4.8 France Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2020-2030
  • Table 4.9 Italy Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2020-2030
  • Table 4.10 Spain Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), Market Share (%), and CAGR (%), 2020-2030
  • Table 4.11 APAC Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), Market Share (%), and CAGR (%), 2020-2030
  • Table 4.12 Japan Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2020-2030
  • Table 4.13 Estimated number of hospitalized patients and deaths due to infectious gastroenteritis among adults aged ≥60 years in Japan
  • Table 4.14 China Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), Market Share (%), and CAGR (%), 2020-2030
  • Table 4.15 India Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2020-2030
  • Table 4.16 Australia Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2020-2030
  • Table 4.17 ASEAN Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2020-2030
  • Table 4.18 Rest of APAC Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2020-2030
  • Table 4.19 Central and South America Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2020-2030
  • Table 4.20 Distribution of positive norovirus and rotavirus cases identified during Epidemiological Surveillance of Gastroenteritis due to Rotavirus, São Paulo, SP, 2010-2016
  • Table 4.21 Brazil Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2020-2030
  • Table 4.22 Argentina Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2020-2030
  • Table 4.23 Rest of Central and South America Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2020-2030
  • Table 4.24 MEA Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), Market Share (%), and CAGR (%), 2020-2030
  • Table 4.25 Norovirus infection in countries of the MENA region between 2000 and 2015
  • Table 4.26 GCC Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), Market Share (%), and CAGR (%), 2020-2030
  • Table 4.27 South Africa Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2020-2030
  • Table 4.28 North Africa Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2020-2030
  • Table 4.29 Rest of MEA Norovirus Vaccines Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2020-2030
  • Table 5.1 Takeda: Revenues 2016-2018 (JPY Million)

List of Figure

  • Figure 4.1 Global Norovirus Vaccines Revenue Forecast ($m), 2020-2030
  • Figure 4.2 Global Norovirus Vaccines Market Share (%), 2022
  • Figure 4.3 Global Norovirus Vaccines Market Share (%), 2025
  • Figure 4.4 Global Norovirus Vaccines Market Share (%), 2030
  • Figure 4.5 North America Norovirus Vaccines Revenue Forecast ($m), 2020-2030
  • Figure 4.6 North America Norovirus Vaccines Market Share (%), 2022
  • Figure 4.7 North America Norovirus Vaccines Market Share (%), 2025
  • Figure 4.8 North America Norovirus Vaccines Market Share (%), 2030
  • Figure 4.9 U.S. Norovirus Vaccines Revenue Forecast ($m), 2020-2030
  • Figure 4.10 Canada Norovirus Vaccines Revenue Forecast ($m), 2020-2030
  • Figure 4.11 EU5 Norovirus Vaccines Revenue Forecast ($m), 2020-2030
  • Figure 4.12 EU5 Norovirus Vaccines Market Share (%), 2022
  • Figure 4.13 EU5 Norovirus Vaccines Market Share (%), 2025
  • Figure 4.14 EU5 Norovirus Vaccines Market Share (%), 2030
  • Figure 4.15 Germany Norovirus Vaccines Revenue Forecast ($m), 2020-2030
  • Figure 4.16 The UK Norovirus Vaccines Revenue Forecast ($m), 2020-2030
  • Figure 4.17 France Norovirus Vaccines Revenue Forecast ($m), 2020-2030
  • Figure 4.18 Italy Norovirus Vaccines Revenue Forecast ($m), 2020-2030
  • Figure 4.19 Spain Norovirus Vaccines Revenue Forecast ($m), 2020-2030
  • Figure 4.20 APAC Norovirus Vaccines Revenue Forecast ($m), 2020-2030
  • Figure 4.21 APAC Norovirus Vaccines Market Share (%), 2022
  • Figure 4.22 APAC Norovirus Vaccines Market Share (%), 2025
  • Figure 4.23 APAC Norovirus Vaccines Market Share (%), 2030
  • Figure 4.24 Japan Norovirus Vaccines Revenue Forecast ($m), 2020-2030
  • Figure 4.25 China Norovirus Vaccines Revenue Forecast ($m), 2020-2030
  • Figure 4.26 India Norovirus Vaccines Revenue Forecast ($m), 2020-2030
  • Figure 4.27 Australia Norovirus Vaccines Revenue Forecast ($m), 2020-2030
  • Figure 4.28 ASEAN Norovirus Vaccines Revenue Forecast ($m), 2020-2030
  • Figure 4.29 Rest of APAC Norovirus Vaccines Revenue Forecast ($m), 2020-2030
  • Figure 4.30 Central and South America Norovirus Vaccines Revenue Forecast ($m), 2020-2030
  • Figure 4.31 Central and South America Norovirus Vaccines Market Share (%), 2025
  • Figure 4.32 Central and South America Norovirus Vaccines Market Share (%), 2030
  • Figure 4.33 Brazil Norovirus Vaccines Revenue Forecast ($m), 2020-2030
  • Figure 4.34 Argentina Norovirus Vaccines Revenue Forecast ($m), 2020-2030
  • Figure 4.35 Rest of Central and South America Norovirus Vaccines Revenue Forecast ($m), 2020-2030
  • Figure 4.36 MEA Norovirus Vaccines Revenue Forecast ($m), 2020-2030
  • Figure 4.37 MEA Norovirus Vaccines Market Share (%), 2025
  • Figure 4.38 MEA Norovirus Vaccines Market Share (%), 2030
  • Figure 4.39 GCC Norovirus Vaccines Revenue Forecast ($m), 2020-2030
  • Figure 4.40 South Africa Norovirus Vaccines Revenue Forecast ($m), 2020-2030
  • Figure 4.41 North Africa Norovirus Vaccines Revenue Forecast ($m), 2020-2030
  • Figure 4.42 Rest of MEA Norovirus Vaccines Revenue Forecast ($m), 2020-2030

List of Companies and Organisations Mentioned in the Report:

  • GlaxoSmithKline
  • Merck
  • Pfizer
  • Sanofi
  • World Health Organization (WHO)
  • Centers for Disease Control and Prevention (CDC)
  • The Child Health Epidemiology Reference Group (CHERG)
  • Merck and Co., Inc.
  • The Vaccine Research Center
  • Takeda
  • WCCT Global
  • Children's Hospital Medical Center
  • LigoCyte Pharmaceuticals, Inc.
  • University of Zurich
  • France Délices Inc
  • Chinese Ministry of Health
  • Institut Pasteur of Shanghai (IPS)
  • Anhui Zhifei Longcom Biopharmaceutical Co Ltd
  • Vaxart
  • Aviragen Therapeutics, Inc.
  • Janssen
  • Cocrystal Pharma, Inc.
  • PanTheryx
  • Zuellig Pharma
  • Zuellig Health Solutions Innovation Centre
  • Calici Therapeutics Inc.